Semaglutide and tirzepatide are the two medications driving the GLP-1 weight-loss conversation in 2026. They are often mentioned in the same breath, and they work in overlapping ways — but they are not the same drug, and they do not produce the same results for everyone. This guide compares semaglutide vs. tirzepatide in plain terms: how each works, how much weight people tend to lose, what side effects to expect, and how to think about choosing.
We are an independent editorial team. We do not prescribe medication or sell it. The goal here is a clear, neutral comparison so you can have a better-informed conversation with a licensed clinician.
The quick version
- Semaglutide is a GLP-1 receptor agonist. Brand names: Ozempic and Wegovy.
- Tirzepatide is a dual GIP/GLP-1 receptor agonist — it acts on two gut-hormone pathways instead of one. Brand names: Mounjaro and Zepbound.
- In clinical trials, tirzepatide produced greater average weight loss than semaglutide.
- Both share a similar side-effect profile, mostly gastrointestinal, and both require gradual dose titration.
That single-vs.-dual mechanism is the heart of the difference. Below is how it plays out in practice.
How each one works
Semaglutide mimics GLP-1, a hormone your gut releases after eating. It slows stomach emptying, helps regulate blood sugar, and signals fullness to the brain — so you feel satisfied sooner and stay satisfied longer.
Tirzepatide does everything semaglutide does on the GLP-1 pathway, and it also activates the GIP receptor. GIP is a second incretin hormone involved in how the body manages blood sugar and fat. The current thinking is that hitting both pathways is part of why tirzepatide tends to drive larger average weight loss, though individual responses vary widely.
Side-by-side comparison
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Drug class | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| Brand names | Ozempic, Wegovy | Mounjaro, Zepbound |
| Average weight loss in trials | Significant | Greater on average than semaglutide |
| Common side effects | Nausea, constipation, diarrhea | Nausea, constipation, diarrhea |
| Dosing | Titrated up gradually | Titrated up gradually |
| Typical compounded cash price (2026) | ~$147–$300/mo | ~$200–$500/mo |
| Typical brand cash price (2026) | ~$1,000–$1,350/mo | ~$1,000–$1,350/mo |
Prices are general 2026 cash-pay ranges and vary by pharmacy and dose. For a fuller cost breakdown, see our GLP-1 cost guide.
Effectiveness: what the trials suggest
Across clinical studies, both medications produce meaningful weight loss, and tirzepatide has shown greater average results than semaglutide. "Average" is the key word. Trial averages describe groups, not individuals — some people respond very strongly to semaglutide, while others see better results on tirzepatide. Factors like your starting weight, diet, activity, dose, and how long you stay on treatment all shape the outcome. There is no way to know in advance exactly how your body will respond to either drug.
Side effects: more alike than different
Both medications share a similar side-effect profile. The most common effects are gastrointestinal — nausea, constipation, and diarrhea — and they tend to be most noticeable when starting or stepping up to a higher dose. Gradual titration exists largely to keep these manageable. For most people the effects ease as the body adjusts, but they can be significant, and some people stop because of them.
Because tirzepatide is often used at doses that drive more aggressive weight loss, some people find its side effects more pronounced — but this is highly individual and not a rule.
Who should not take either medication
The serious contraindications are the same for both drugs. You should not take semaglutide or tirzepatide if you have:
- A personal or family history of medullary thyroid carcinoma or MEN2 (multiple endocrine neoplasia type 2).
- A history of pancreatitis.
- A current or planned pregnancy.
These are not the only considerations. A licensed clinician needs your full medical history — other conditions and medications can matter too. Our safety overview covers the broader picture.
Dosing and what to expect over time
Neither drug starts at its full strength. Both are titrated up gradually — you begin at a low dose and step up over weeks or months, giving your body time to adjust and keeping side effects more manageable. This matters for two reasons. First, your early experience is not a preview of your maintenance dose; results and side effects often shift as the dose climbs. Second, the lowest advertised price often reflects a starting dose, so your cost may rise as you titrate up. Ask any clinic to show you the full dose-by-dose schedule and pricing before you commit.
Both medications are intended to be paired with diet and activity changes, not used in isolation. They reduce appetite and help you feel full, but the long-term outcome still depends on the habits built alongside them. Many clinicians also frame these as ongoing treatments rather than short courses — weight regain is common after stopping, which is worth discussing up front.
How to choose between them
There is no universal "better" drug. A few questions that tend to guide the decision:
- How much weight do you want to lose, and how fast? Tirzepatide's higher average results appeal to some people, but more is not always the right goal for everyone.
- How sensitive are you to side effects, or to cost? Semaglutide is often the lower-priced option, especially in compounded form.
- What does your clinician recommend given your history? This is the deciding factor. Your contraindications, other medications, and goals matter more than any trial average.
It is also worth knowing that not every clinic offers both drugs. If you want the flexibility to start on one and switch, look for a provider with a broad medication menu — Gala Health, the top-rated clinic we track, carries the widest selection. You can compare options across providers in our clinic comparison.
Frequently asked questions
Is tirzepatide better than semaglutide?
On average, tirzepatide produced greater weight loss than semaglutide in clinical trials. But "better" depends on you — your goals, side-effect tolerance, budget, and medical history. Some people do very well on semaglutide. A licensed clinician is the right person to weigh these factors.
Can I switch from semaglutide to tirzepatide?
Many people do switch, often guided by results or tolerability. Any switch should be supervised by a clinician, who will manage dosing and titration. Not every clinic offers both, so a broad medication menu helps if you want that flexibility.
Do they have different side effects?
The side-effect profiles are largely the same — mostly gastrointestinal, such as nausea, constipation, and diarrhea — and tend to be most noticeable during dose increases. Severity varies from person to person.
Which one is cheaper?
Semaglutide is generally the lower-cost option, especially in compounded form (roughly $147–$300/mo in 2026 versus about $200–$500/mo for compounded tirzepatide). Brand-name versions of both run much higher. See our cost-ranked clinic list for details.
Are compounded versions of these drugs FDA-approved?
No. Compounded semaglutide and tirzepatide are made by licensed pharmacies but are not FDA-approved, meaning they are not reviewed for safety, effectiveness, or quality the way brand-name products are. Discuss the trade-offs with a clinician.
This article is educational information, not medical advice. It does not replace consultation with a qualified healthcare provider. Whether semaglutide or tirzepatide is appropriate for you — and at what dose — is a decision made by a licensed clinician who knows your medical history.
